Merck & Co. is in late-stage talks to acquire Prometheus Biosciences Inc., according to people familiar with the matter, a move that could give the big drugmaker promising immune disease treatments.
Saturday, September 5, 2026
WSJ News Exclusive | Merck in Late-Stage Talks to Acquire Prometheus Biosciences
Leave Comment
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/tronc/4NCOK2G4GIIUKB7HHX3LXM73WI.jpg)
EP NEWSROOM
© 2025 Edinburg Post or its affiliated companies.